Life Sciences
Aim of funding: 
HMRC Advance Assurance received: 



T-EDTA Limited was established to develop anti-biofilm technologies and infection control products. Anti-biofilm is used in advanced wound care products using the anti-biofilm agents tri sodium/tetra sodium EDTA (‘t-EDTA’). A biofilm is a group of microorganisms in which cells stick to each other and often adhere to a surface, such as wound. As such, they represent a major risk of woundsite infection. EDTA is a chemical which can inhibit the development of such biofilms.

Biofilms are a major problem for human infections and medical device related infections due to their becoming resistant to antibiotics, with the result being wounds that are slow to heal, or not healing/remaining open. The patented tri and tetrasodium EDTA (‘T-EDTA’) can be used to prevent and control infection in three specific areas; advanced wound care, catheters and consumer wellness (Skin/foot fungal infections).


The global wound care market is expected to reach USD20.4bn by 2021 from USD 17.0bn in 2016, growing at a compounded annual growth rate of 3.6% from 2016 to 2021 [1]. The market has three core segments: Advanced Wound Care, traditional professional use and traditional consumer use. Advanced wound care products which incorporate advanced antimicrobials and antibiofilm agents are urgently required and have now become an increasing need in all areas of wound management.Among the above highlighted segments, the advanced wound care management product segment commanded the largest share in 2015 and is forecasted to be the fastest-growing segment in the wound care market. Factors such as rising awareness regarding new technologies for wound care, government support in the form of funding and rising diabetic and aging population are driving the growth of the wound care market. 

Based on geography, the global wound care market is segmented into North America, Europe, Asia, and the Rest of the World. North America was predicted to account for the largest share of the market by the end of 2016. This large share can be attributed to various factors, including the increase in acute and chronic conditions such as diabetic foot ulcers, venous ulcers as well as pressure ulcers and government support for wound care research in the form of funds. 

[1] http://www.marketsandmarkets.com/Market-Reports/wound-care-market-371.html?gclid=Cj0KEQjwxPbHBRCdxJLF3qen3dYBEiQAMRyxS9gD3Zza5OTO2Ov9Qggzxy6gc-M2qrUVCwAtjsanP_YaAl9Y8P8HAQ

Information on this webpage relates to and is provided by Deepbridge Advisers Limited.

The content of this webpage should not be construed as financial advice. Any decision to invest should be made only on the basis of the relevant documentation for each investment. Past performance is not necessarily a guide to future performance. The value of an investment may go down as well as up and investors may not get back the full amount invested. Investments in small unquoted companies carry an above-average level of risk. These investments are highly illiquid and as such, there may not be a readily available market to sell such an investment. Deepbridge Capital LLP, Deepbridge Advisers Limited and Enterprise Partners LLP (together "the Sponsors," or "Sponsor) do not provide specific individual advice on the suitability of investments with regard to a potential investor's individual circumstances, risk tolerance or investment objectives and investors should seek independent financial advice if they are in any doubt whether a product is suitable for them.